|Bid||69.00 x 900|
|Ask||72.00 x 900|
|Day's Range||69.24 - 72.50|
|52 Week Range||33.13 - 76.98|
|Beta (5Y Monthly)||1.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020 - Mar 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||87.83|
Editor's note: This story has been updated to reflect the FDA's approval Friday of Agile Therapeutics' hormonal contraceptive patch Twirla. Biotech stocks were quiet in the week ending Feb. 14 amid some ...
Biotech stocks have come under some selling pressure in the new year. However, January did witness some strong stock-specific upward moves, especially with stocks leveraged to the Wuhan coronavirus epidemic. ...
– Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism –– Positive.
Esperion (ESPR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the MAA for the bempedoic acid tablet, recommending approval for the treatment of hypercholesterolemia and mixed dyslipidemia. The positive CHMP opinion was achieved with no Oral Explanation as the Rapporteurs found there were no substantive issues that needed to be discussed with the CHMP at the time of the vote.
Anyone researching Esperion Therapeutics, Inc. (NASDAQ:ESPR) might want to consider the historical volatility of the...
ANN ARBOR, Mich., Jan. 07, 2020 -- Esperion (NASDAQ:ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will present at the 38th Annual J.P..
Esperion (ESPR) today announced that, on January 2, 2020, the Compensation Committee of Esperion’s Board of Directors granted 358 restricted stock units (RSUs) to one new colleague under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each RSU will vest as to twenty-five percent of the shares on the one-year anniversary of the recipient's start date, and will vest as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following the anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates.
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize the launch.
ANN ARBOR, Mich., Nov. 17, 2019 -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the.
– Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – – Over 52-Weeks, Overall Adverse Events in the Bempedoic Acid Treatment.
Potential Esperion Therapeutics, Inc. (NASDAQ:ESPR) shareholders may wish to note that the President, Timothy...
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...
ANN ARBOR, Mich., Nov. 07, 2019 -- Esperion (NASDAQ:ESPR), today announced that the company will participate in fireside chats at the following conferences: Credit Suisse 28th.
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -25.37% and 5.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ANN ARBOR, Mich., Nov. 06, 2019 -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended.
ANN ARBOR, Mich., Nov. 04, 2019 -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the.
ANN ARBOR, Mich., Oct. 29, 2019 -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets.
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]
Esperion (ESPR) announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical Innovation Summit on Wednesday, October 23rd. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...